PA) was closing in on a roughly $20 billion deal to buy U.S. biotech group Genzyme (GENZ.O) while pausing to take a final look at the books, sources familiar with the matter said. Talks about a takeover of Genzyme continued on Monday ...
Genzyme Corporation (NASDAQ:GENZ) recently announced that it has entered into an agreement with Japanese company, Sekisui Chemical Co., Ltd. for the sale of its diagnostic products business. Sekisui will acquire Genzyme's diagnostic ...
All of the freshest reports have the Genzyme Corporation (NASDAQ: GENZ) buyout discussions between Sanofi-Aventis (NYSE: SNY) as being a friendly merger. The first discussions noted by the WSJ were a $67 to $70 per share price range.
